Shows / BiotechTV - News
BiotechTV - News
This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.
Episodes
BiotechTV - NewsJefferies London: Zealand Pharma CEO Adam Steensberg believes that amylins will overtake GLPs as the backbones of obesity treatments in the future
He discusses Zealand's partnership with Roche, and new data that will be coming next year. Plus, the company's partnership with Boehringer on survodutide.
BiotechTV - NewsJefferies London: Nanobiotix has a new platform that is meant to help RNA/DNA-based therapies, gene therapies, oncolytic viruses and other liver-delivered medicines have better efficacy
CEO Laurent Levy introduces us to the company's Curadigm Nanoprimer platform and explains its potential use cases. Plus, an update on the company's JNJ…
BiotechTV - NewsJefferies London: Jefferies Global Chairman of Healthcare Philip Ross discusses the environment for biotech and deals
He shares his take on the capacity for pharma to do more buying, and list his favorite areas of science, which include I&I, CNS/Neurology, and modalities such…
BiotechTV - NewsJefferies London: Chief Scientific Officer Tony Wood covers the latest highlights in GSK's pipeline, including oncology, respiratory, and inflammation
He mentions momelotinib, Blenrep, B7-H3, depemokimab, efimosfermin, IL-33, TSLP, and more. Plus, GSK's dealmaking strategy.
BiotechTV - NewsJefferies London: Zymeworks had double-news during London Life Science Week - a P3 success for its HER2 bispecific in gastroesophageal cancer and it also launched a new royalty model
CEO Kenneth Galbraith explains the new dual business focus and walks us through the topline HER2 data.
BiotechTV - NewsJefferies London: Protagonist Therapeutics CEO Dinesh Patel responds to takeout speculation and discusses the company's programs and culture of partnering
He covers the company's oral IL-23 (partnered with JNJ), rusfertide (partnered with Takeda), and a new early stage obesity program.
BiotechTV - NewsJefferies London: BeOne Medicines announced a phase 3 success for its HER2 bispecific today in gastric cancer. John Olyer walks us through that and the whole pipeline
He hit on earnings, the HER2, degraders, and what BeOne is looking for in potential partners.
BiotechTV - NewsJefferies London: Sofinnova Partners announced a new $750M fund XI today that will invest in early stage companies in biotech
Chairman and managing partner Antoine Papiernik tells us about the fund and how he expects to deploy it. Plus, the current state of European biotech.
BiotechTV - NewsJefferies London: Jefferies M&A Banker Chris Roop shares his take on the environment for deals in biotech
He expects deals to continue in 2026, and says that the bidding wars we have seen recently are likely deal specific.
BiotechTV - NewsLegend Biotech CEO Ying Huang shares a post-earnings update from the company's new R&D Center in Philadelphia
He describes how Legend is no longer capacity constrained for it's CAR-T treatment, Carvykti, and previews the upcoming ASH conference.
BiotechTV - NewsApogee will have at lest four key trial readouts for its half-life optimized IL-13 program next year, including monotherapy trials and in combination with OX40L and TSLP.
CEO Michael Henderson walks us through what will be a busy year for the company.
BiotechTV - NewsAvalo Therapeutics is developing a high affinity IL-1β for hidradenitis suppurativa - key phase 2 data will come next year
CEO Garry Neil describes the target and how he believes Avalo's therapy has especially high affinity. Approximately 1% of the population is believe to have HS.
BiotechTV - NewsStifel's Head of Global Equity Capital Markets Seth Rubin describes the investor feedback he is hearing about the sector lately and the fundraising environment for companies
He says that investors are placing fewer, but larger bets on companies lately, and he expects a 'healthy' IPO market in 2026.
BiotechTV - NewsSionna Therapeutics is trying to improve the treatment paradigm for cystic fibrosis by targeting NBD1, a nucleotide binding-domain of the CFTR protein, and restore healthy function for all
CEO Mike Cloonan describes the unmet need for better treatments that exists today in CF, and discusses Sionna's development plans.
BiotechTV - NewsStifel's I&I expert Alex Thompson shares his take on the environment and discusses names he covers that have key catalyst events
He comments on Kymera, Apogee, Avalo, Veridian, Moonlake, Spyre, and Oruka.
BiotechTV - NewsCelcuity release what it believes is practice changing breast cancer data with its multi-target PAM inhibitor. Co-Founder & CEO Brian Sullivan describes why he believes the data is so important
He discusses the pathway and gedatolisib's ability to cover it holistically. Plus, future plans for filing and additional data in breast cancer and beyond.
BiotechTV - NewsSpyre Therapeutics is developing a basket of therapies (α4β7, TL1A, and IL-23) that are meant to have a greater half-life and work better in combination that current therapies for IBD and rheumatology
CEO Cameron Turtle describes the improvements Spyre is making in its therapies. 2026 is going to be a data rich year for IBD.
BiotechTV - NewsVicore Pharma is leveraging in understanding the Renin-Angiotensin System (RAS) to develop angiotensin II type 2 receptor agonists for IPF and beyond
CEO Ahmed Mousa walks us through the sciences and describes how data stacked up against a synthetic external control that was presented at a medical meeting…
BiotechTV - NewsThe early part of 2026 is going to be a key time for REGENXBIO's gene therapies, with an FDA decision date schedule for Hunter's Syndrome and a pivotal trial readout in DMD
CEO Curran Simpson describes REGENXBIO's expertise in AAV, and walks us through the company's programs.
BiotechTV - NewsAardvark Therapeutics' approach to obesity is to inhibit hunger (vs appetite). It has a key pivotal trial scheduled to read in Prader-Willi syndrome early next year, and is also working on weight loss
Founder and CEO Tien Lee describes how Aardvark's approach focuses on the gut-brain axis.
BiotechTV - NewsStifel's Head of Therapeutics Paul Matteis shares his take on the sector and discusses names he covers that have key catalyst events
He shares his thoughts on uniQure, Xenon, Alkermes, Compass Pathways, GH Research MindMed, and Dyne.
BiotechTV - NewsUpstream Bio is focused on the TSLP space, and has a unique approach of targeting the receptor as opposed to the ligand. It might give them a better dosing and efficacy profile.
CEO Rand Sutherland describes TSLP pathway and Upstream's choice to hit the receptor, and how this could define the company's competitive profile.
BiotechTV - NewsAdaptyx announced $14M in additional seed financing to fund the development of a continuous health monitoring device that aims to track small molecules, electrolytes, hormones, drugs, and proteins
Co-Founder & CEO Vijit Sabnis describes the company's goal of taking the field from continuous glucose monitoring to capturing a wider range of human…
BiotechTV - NewsAulos Bioscience presented phase 2 data at SITC for its antibody that binds to IL-2 and prevents CD25 binding - showing responses in melanoma and lung
CEO Aron Knickerbocker walks us through the data and describes why he believes imneskibart's ability to show a higher Teff/Treg ratio in patients, and how it…
BiotechTV - NewsEnara Bio publicly announced its first cancer specific 'dark genome antigen' target at SITC - DARKFOX, an alternative open reading frame associated with FOXM1
CEO Kevin Pojasek describes the past challenge of drugging FOXM1, and why he believes DARKFOX will be an ideal target for the company's T-cell engager platform.
BiotechTV - NewsCompugen is standing firm on its belief that TIGIT will ultimately succeed with Fc reduced/silent constructs
The company's new CEO Eran Ophir discusses the computational work that when into Compugen's understanding of TIGIT biology, and he walks us through their…
BiotechTV - NewsSynthekine presented data at SITC on its α/β-IL-2 receptor biased partial agonist showing a 53% response rate in PD-L1 negative nonsquamous NSCLC
Co-Founder & CEO Debanjan Ray walks us through learnigs the IL-2 space has seen over the years, and describes why Synthekine is targeting both the α and β…
BiotechTV - NewsMarengo Therapeutics has presented data at ESMO and SITC showing that its lead program, which is designed to activate Vβ6/10 T cells, is active in multiple tumor types
CEO Zhen Su walks us through the data, which had 46 efficacy-evaluable patients and showed a 20% ORR and 80% DCR across multiple tumor types.
- BiotechTV - News
Brain shuttle technologies have been in the news a lot lately. Natalie Ricciardi explains what you need to know about 1st and 2nd generation technologies in development.
She and her colleagues at inThought Research recently published a report summarizing the brain shuttle technology research landscape in the biotech sector.
BiotechTV - NewsMenlo Ventures published a report showing that the healthcare industry is the leading adopter of AI - one of the co-authors shares the key takeaways
Menlo Ventures Partner, and co-author of the report, Derek Xiao talks about how AI is improving the P&L of health systems and helping with staffing shortages…
BiotechTV - NewsBIO-Europe 2025: Spain based ARTHEx Biotech is a European player in the DM1 space, and believes its microRNA strategy offers a dual benefit that it says is unique to the field
CEO Frédéric Legros walks us through the science and explains why he believes ARTHEx has a unique approach compared to others we have seen in the field. The…
BiotechTV - NewsBIO-Europe 2025: Sparrow Pharmaceuticals raised a $95M series B last month - it will be testing its cortisol depleting HSD1 inhibitor in type 2 diabetes
CEO Robert Jacks describes the history of learning about how Sparrow's asset lowered cortisol in Cushing's syndrome, and new data suggesting that doing so…
BiotechTV - NewsBIO-Europe 2025: Topas Therapeutics is delivering nanoparticles to the liver to establish tolerance in T-cells for autoimmune and immune-mediated disease - it recently had intriguing data in celiac
CEO Hugo Fry describes the scientific idea behind antigenic tolerization, and discusses Topas' recent PoC data that was presented at Digestive Disease Week.
BiotechTV - NewsBIO-Europe 2025: Step Pharma has 'followed the genetics' to be the first company to target CTPS1 inhibition for cancer - CEO Andrew Parker walks us through this unique science
He explains the story of this enzyme and the biology of how CTPS1 and CTPS2 interact. Step is in the clinic in lymphoma and solid tumors, and recently raised a…
BiotechTV - NewsBIO-Europe 2025: Barcelona based Connecta Therapeutics is moving its neuroplasticity modulator for fragile X syndrome into a phase 2a study after completing first in human studies late last year
CEO Jordi Fàbrega and CFO Josep Prous discusses the asset, CTH120, which is a NCE and proprietary to Connecta.
BiotechTV - NewsBIO-Europe 2025: Switzerland based ReproNovo is focused on reproductive health - with two clinical stage assets and three indications it is going after
CEO Jean Marie Duvall describes the company's programs, one focused on male inferitliy and another that may have dual purposes of helping with embryo…
BiotechTV - NewsBIO-Europe 2025: Anavo Therapeutics is focused on phosphatases - and is publicly talking about its two lead programs for the first time
CEO Birgit Zech and CSO Edward Holson discuss the unique beginning of the company (a powerpoint deck), and the difficulties in drugging phosphatases. Plus, the…
BiotechTV - NewsBIO-Europe 2025: Herantis Pharma is developing HER-096 for Parkinson's, a blood-brain-barrier penetrant small peptide molecule that is designed to mimic the activity of CDNF
CEO Antti Vuolanto walks us through recent phase 1b data, which reported safety and PK data. Biomarker data will be forthcoming before the end of the year.
BiotechTV - NewsBIO-Europe 2025: Valneva's partner Pfizer has been running a big trial of a Lyme disease vaccine that has covered the last three seasons - it will read out in the first part of next year
Valneva CEO Thomas Lingelbach walks us through this program by describing how the vaccine is designed and how the study has been conducted. Plus, his comments…
BiotechTV - NewsRoche will pay Manifold Bio $55M up front, and up to $2B in biobucks, to collaborate on multiple next-generation brain shuttles for neurological diseases
Manifold Co-Founders Gleb Kuznetsov and Pierce Ogden explain how Manifold is working on next generation shuttles, which means going beyond transferrin. They…
BiotechTV - NewsBIO-Europe 2025: ReNewVax CEO Neil Murray believes the antigens the company has found will enable it to develop a pneumococcal vaccine that targets all ca.100 existing variants
He describes the unmet need for a better vaccine than those already on the market, and says he is looking for a lead investor for a series A at BIO-Europe.
BiotechTV - NewsBIO-Europe 2025: Abivax CEO Marc de Garidel discusses physician and payor feedback after obefazimod's phase 3 UC induction readouts, and next steps regarding maintenance and Crohn's
He describes the mechanism of the therapy, as well the data and commercial landscape for UC. Plus, how he thinks about combos and business development.
BiotechTV - NewsBIO-Europe 2025: AAVantgarde Bio, which is working on gene therapies for inherited retinal diseases that are caused by mutations in large genes, closed a $141M series B raise today
CEO Natalia Misciattelli describes the lead programs for Stargardt Disease and Usher 1B Syndrome, and how AAVantgarde is able to solve the problem of…
BiotechTV - NewsMathai Mammen recaps the first clinical data Parabilis Medicines reported on its beta-catenin program earlier this month at EMSO and AACR-NCI-EORTC 2025. Plus, degraders for prostate cancer, and more.
He explains the company's "Helicon" peptide platform, and why he believes it is well suited to target previously undruggable problems like beta-catenin. Then…
BiotechTV - NewsBiotechTV visited South San Francisco based Noetik and saw how they are digitizing tumor samples and using AI to sort through the complexity of the biology for drug discovery
Co-Founder and CEO Ron Alfa walked BiotechTV's Ryan Flinn through how machine learning is taking cancer cell biology beyond the microscope.
BiotechTV - NewsSonoma Biotherapeutics announced early clinical data today in a late-breaker at #ACR25 for its CAR-Treg to treat rheumatoid arthritis. Co-Founders Jeff Bluestone and Fred Ramsdell walk us through it.
They explain why they believe a Treg based cell therapy is the right approach for autoimmune conditions, and describe the construct of this particular product…
BiotechTV - NewsZag Bio launched today with $80M, and aims to tackle autoimmune disease by using antibodies to reprogram how Tregs and Teffs are created in the thymus. The lead indication will be Type 1 diabetes
CEO Jason Cole walks us through this unique science, which is based on work that co-founder Diane Mathis and colleagues published in Cell in 2022. The T1D…
BiotechTV - NewsHemab Therapeutics, a company specializing in developing treatments for bleeding disorders, announced a $157 million series C raise today. CEO Benny Sorensen describes the work and unmet need.
The company's lead program, a bi-specific called Sutacimig, has already reported phase 2 data for Glanzmann Thrombasthenia, and will start a pivotal in 2026…
BiotechTV - NewsWeave Bio, which raised a $20M series A this month, is aiming to use software and LLMs to automate and streamline regulatory submissions for drug development
Co-Founder & CEO Brandon Rice says that in one project it worked on with a pharma, Weave's technology took only 3 hours to draft regulatory documents what…
BiotechTV - NewsAhead of a year of increased clinical activity, Entrada Therapeutics' CEO Dipal Doshi discusses the company's EEV platform, DMD programs, and a Vertex partnership in DM1
He walks us through exon 44 and 45 programs, which will both likely have clinical readouts in 2026. Meanwhile, a $350M cash position gives Entrada the ability…
BiotechTV - NewsDisc Medicine CEO John Quisel describes the process of becoming among the first companies to receive FDA's new Commissioner's National Priority Voucher (CNPV)
He describes how Disc applied for and was awarded a CNPV for Bitopertin, which treats a rare disease that causes extreme sensitivity to sunlight. Plus, quickly…
BiotechTV - NewsBiotech entrepreneurs share advice on navigating through today's uncertain times: "It's going to be okay"
MassBio CEO Kendalle Burlin O'Connell moderates a discussion with Normunity CEO Rachel Humphrey and Gallop Oncology CEO Luba Greenwood about how they are…
BiotechTV - NewsFlagship Pioneering announced its newest company to emerge out of stealth mode today: Expedition Medicines. It is leveraging generative design for small molecule covalent chemistry
Co-Founder and CEO Molly Gibson explains the science behind the new company and the technology and equipment it uses for the work. Expedition has been funded…
BiotechTV - NewsBiotech veteran Oz Azam has become the CEO of Cue Biopharma. He walks us through the science behind the company's new focus in autoimmune that has him excited about the opportunity
He describes CUE-401, which combines a TGF-beta breathing-mask moiety with an interleukin (IL-2) mutein, and CUE-501, a Boehringer Ingelheim partnered program…
BiotechTV - NewsGet to know Women In Bio, and how this organization helps women at all stages of their careers in biotech
During a meeting in Boston at Portal Innovations where Women in Bio (WIB) was working on its 'Boardroom Ready' initiative, Dianne Keen-Kim (National President…
BiotechTV - NewsEmeryville, CA based Profusa is developing an injectable biosensor that aims to generate biochemistry information for users in real time
Chairman & CEO Ben Hwang describes the idea behind Profusa's approach, and how he believes it delivers more robust and actionable information than purely…
BiotechTV - NewsPepGen's CEO James McArthur gives an overview of the company's recent data in myotonic dystrophy type 1, which showed a mean splicing correction of 53.7% at the 15 mg/kg dose
He describes the science behind PepGen's "Enhanced Delivery Oligonucleotide (EDO)" platform, and explain how he believes it gives the company a differentiated…
BiotechTV - NewsBenchtalk 2025: Kate Haviland discusses the $9B+ acquisition of Blueprint by Sanofi, being chair of Fulcrum, her thoughts on M&A, and what is interesting in biotech today
The CEO of Blueprint (up to the acquisition) discusses the company's success factors, and being led to immunology by the science. Plus, why she believes an…
BiotechTV - NewsBenchtalk 2025: Generate:Biomedicines' VP of Informatics Stephen Kottmann describes the investments in technology that ensures only the highest quality data returns back into its models
He walks us through the design, build, test, learn model that is the foundation of Generate's approach to drug development.
BiotechTV - NewsBenchtalk 2025: Benchling Co-Founder & CEO Sajith Wickramasekara describes why he believes science and Benchling are entering a new era of speed and cost of R&D
He welcomes us to Benchtalk 2025, which had more than 800 scientists register this year, and describes how AI and other computational advances are allowing…